I disagree, Oral-lyn a stage II clinical trials completed and reformulated product to re-start a (potentially not even necessary full) phase III trial, which has the potential to generate triple digit million dollar revenues (once FDA approved) should have a really significant value. That alone should have a value of easily 10x the 3,5 million that were paid for all the GNBT remains.

It is a shame that the trustee has not even bothered propperly investigating a fair value of GNBT's product pipeline.